

(19) World Intellectual Property
Organization
International Bureau



10 JAN 2005



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/006891 A2

(51) International Patent Classification⁷: **A61K 9/127**

(21) International Application Number:
PCT/CH2003/000453

(22) International Filing Date: 8 July 2003 (08.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02014991.0 10 July 2002 (10.07.2002) EP

(71) Applicant and

(72) Inventor: **BRON, Denis** [CH/CH]; Mühlefeld 12,
CH-5016 Obererlinsbach (CH).

(74) Agent: **E. BLUM & CO.**; Vorderberg 11, CH-8044 Zürich
(CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DELIVERY SYSTEM FOR PHARMACEUTICAL AGENTS

(57) **Abstract:** The present invention relates to a delivery system for pharmaceutical agents. Said delivery system comprises liposomes which comprise in their internal compartment a pharmaceutical agent to be delivered and which have linked to their external surface the cell adhesion molecule NCAM or a fragment thereof. In a preferred embodiment said pharmaceutical agent is a DNA, preferably a cDNA which is operably linked to a gene expression construct.

WO 2004/006891 A2